Diabetes interaction triage
Repaglinide interactions: avoid clopidogrel and do not use gemfibrozil
Two interactions can increase the same drug exposure but have different label instructions. Repaglinide with clopidogrel and repaglinide with gemfibrozil should not be reduced to a single generic instruction to monitor glucose.
Sources checked October 11, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Name the exact interacting drug
The repaglinide label prohibits concomitant gemfibrozil. Its interaction table reports increased repaglinide exposure and directs not to administer the combination. Monitoring alone does not turn this contraindication into a supported regimen.
For clopidogrel, the label says to avoid concomitant use. If it cannot be avoided, it gives a restricted initiation dose and maximum daily dose. Preserve that distinction rather than assigning the same management to every CYP2C8 interaction.
Apply both the per-meal dose and daily maximum
When clopidogrel cannot be avoided, the label says to initiate repaglinide at 0.5 mg before each meal and not exceed 4 mg total daily. Increased glucose-monitoring frequency may be required. An answer that mentions only the 4 mg ceiling misses the initiation instruction.
This is not permission to start an interacting combination casually. The clinical team must establish why concomitant use cannot be avoided and choose the regimen. The restriction is a labeled fallback, not the preferred first plan.
Keep meal timing and missed meals in the plan
Repaglinide is taken before meals, and patients should skip the scheduled dose when a meal is skipped to reduce hypoglycemia risk. Changing meal patterns and interacting medicines can affect risk even when the written daily maximum is respected.
Ask about actual meal intake and glucose events. An interaction alert can explain why exposure increased, but it does not replace assessment of current hypoglycemia or identify the correct regimen without patient-specific facts.
Do not make one interaction table universal
The same label gives other instructions for cyclosporine and enzyme inhibitors or inducers. Their existence does not weaken the gemfibrozil prohibition. Read the actual named row before recommending a dose adjustment.
For an exam question, classify the combination first, then supply the exact relevant limit. For a real patient, prescriber review and clinical monitoring remain necessary. Do not infer that a lower numerical dose automatically makes every prohibited pair safe.
A worked case
A patient takes repaglinide 2 mg before each of three meals. Clopidogrel is newly prescribed, and gemfibrozil is also listed. A draft response says to continue all medicines and monitor glucose. Identify the failures.
- Gemfibrozil with repaglinide is contraindicated.
- Clopidogrel should be avoided; the unavoidable-combination pathway begins at 0.5 mg per meal and limits daily repaglinide to 4 mg.
- The current repaglinide schedule totals 6 mg, above that clopidogrel limit.
Answer: This needs interaction and regimen review, not monitoring alone. Do not assume reducing the dose makes the gemfibrozil pair acceptable.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Is repaglinide with gemfibrozil a monitor-only interaction?
No. It is contraindicated.
2. What daily ceiling applies if clopidogrel cannot be avoided?
4 mg total daily, with the labeled 0.5 mg per-meal initiation instruction.
3. What happens to the scheduled repaglinide dose when the meal is skipped?
Skip that dose.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.